UTHR Stock: Price, Earnings History and SEC Filings
United Therapeutics Corporation (UTHR) last traded at $598.72, up 0.87% on the latest session and up 10.5% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $7.27 against an analyst estimate of $6.82, a beat of 6.6%.
$598.72 +0.87%
1 month+10.49%
52-week high$609.99
52-week low$430.02
Volume518,240
ExchangeNasdaqGS
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
UTHR earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 5, 2026 | $7.27 | $6.82 | +6.60% |
| Mar 2026 | May 6, 2026 | $5.82 | $6.73 | -13.52% |
| Dec 2025 | Feb 25, 2026 | $7.70 | $6.78 | +13.57% |
| Sep 2025 | Oct 29, 2025 | $7.16 | $6.89 | +3.92% |
UTHR beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for UTHR
SEC filing data is not available right now. You can search for UTHR on SEC EDGAR.
UTHR news
- SGIOY vs. UTHR: Which Stock Is the Better Value Option?Oct 30, 2026 · finance.yahoo.com
- OmniAb, Inc. (OABI) Reports Q3 Loss, Tops Revenue EstimatesOct 30, 2026 · finance.yahoo.com
- Why Did Insmed Stock Jump?Oct 30, 2026 · trefis.com
- United Therapeutics (UTHR) Cleared To Start Trial For New Pulmonary Hypertension TherapyOct 29, 2026 · finance.yahoo.com
- Insmed Soars 12% on $400 Million Brinsupri Quarter as U.S. Launch “Continues to Exceed Expectations”Oct 29, 2026 · tikr.com
- Earnings Preview: Collegium Pharmaceutical (COLL) Q3 Earnings Expected to DeclineOct 29, 2026 · finance.yahoo.com
- United Therapeutics Receives FDA Clearance to Begin Clinical Trial of Inhaled PAH TreatmentOct 28, 2026 · investorshub.advfn.com
- Liquidia Gears Up to Report Q3 Earnings: What Can Investors Expect?Oct 28, 2026 · finance.yahoo.com
About United Therapeutics Corporation
United Therapeutics Corporation (UTHR) is a US-listed public company on Nasdaq.